Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies - United States, September 2021-February 2022

Details

• Personal Author:
  Clarke, Kristie E. N. ; Jones, Jefferson M. ; Deng, Yangyang ; Nycz, Elise ; Lee, Adam ; Iachan, Ronaldo ; Gundlapalli, Adi V. ; Hall, Aron J. ; MacNeil, Adam
• Corporate Authors:
  CDC COVID-19 Emergency Response Team ; ICF International
• Description:
  In December 2021, the B.1.1.529 (Omicron) Variants of SARS-CoV-2, the Virus that causes COVID-19, became predominant in the U.S. Subsequently, national COVID-19 case rates peaked at their highest recorded levels. Traditional Methods of disease Surveillance do not capture all COVID-19 cases because some are asymptomatic, not diagnosed, or not reported; therefore, the proportion of the population with SARS-CoV-2 antibodies (i.e., seroprevalence) can improve understanding of population-level incidence of COVID-19. This report uses data from CDC's national commercial laboratory seroprevalence study and the 2018 American Community Survey to examine U.S. Trends in infection-induced SARS-CoV-2 seroprevalence during September 2021-February 2022, by age group. ; The national commercial laboratory seroprevalence study is a repeated, cross-sectional, national survey that estimates the proportion of the population in 50 U.S. states, the District of Columbia, and Puerto Rico that has infection-induced antibodies to SARS-CoV-2.† Sera are tested for anti-nucleocapsid (anti-N) antibodies, which are produced in response to infection but are not produced in response to COVID-19 vaccines currently authorized for emergency use or approved by the Food and Drug Administration in the U.S. ; Suggested citation for this article: Clarke KE, Jones JM, Deng Y, et al. Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies - U.S. September 2021-February 2022. MMWR Morb Mortal Wkly Rep 2022;71. ; mm7117e3.htm?s_cid=mm7117e3_w ; mm7117e3-H.pdf
• Subjects:
  • Antibodies, Viral/blood
  • COVID-19
  • COVID-19 Serological Testing
  • SARS-CoV-2
  • Seroepidemiologic Studies
• Source:
  MMWR: Morbidity and Mortality Weekly Report 2022; v. 71 Early Release
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• DOI:
  http://dx.doi.org/10.15585/mmwr.mm7117e3
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Pubmed ID:
  35482574
• Pubmed Central ID:
  PMC9098232
• Document Type:
  Journal Article
• Place as Subject:
  United States
• Pages in Document:
  3 pdf pages
• Volume:
  71
• Download URL:
  https://stacks.cdc.gov/view/cdc/116722/cdc_116722_DS1.pdf
• File Type:
  [PDF - 102.00 KB]
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:8244cbf852c2f338614ae187a540aaa72cff9f5b534bdb7bdc649850dee78f8ce4262de1d3feba2b66402d042696340c4793f33a01854ad07452ae34c79b1c5f